The HSPs are immune adjuvants that are capable of binding tumour antigens and interacting with antigen-presenting cells to mediate a CD8 T-cell response (Udono et al, 1994; Todryk et al, 2000; Castelli et al, 2001; Matsutake and Srivastava, 2001). The gene discussed is CD8A; the disease is neoplasm.